TransMedics Group Inc vs Vanguard High Dividend Yield ETF — how do they compare? TransMedics Group Inc trades at $77.63 (market cap $2.74B), while Vanguard High Dividend Yield ETF trades at $158.79 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 36.8× TransMedics Group Inc's market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| TMDX | VYM | |
|---|---|---|
Market Cap | $2.74B | $100.80B |
Volume | 949,331 | 908,176 |
Sector | Health | — |
52-Week High | $150.42 | $167.03 |
52-Week Low | $61.99 | $137.47 |
Typical Hold Time | 24 Days | 138 Days |
Enterprise Value | $3.13B | — |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
VYM trades at $158.56, up 0.7% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD and IDV. Support sits at $156, with resistance at $159-160. Recent news questions its stock selection methodology after holding Intel and Walgreens through dividend cuts.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include sector concentration in dividend-cut-prone stocks and inflation persistence. Opportunities lie in its low expense ratio and broad diversification across nearly 600 holdings for income-focused investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →